Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production
Berlin, Germany, and Vienna, Austria, April 19th: ProBioGen AG, a leading specialist for contract development and manufacturing of complex glycoproteins and EUCODIS Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize EUCODIS’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.
Scope of ChitoTex is to develop and produce new insect chitosan and chitosan based functional coatings for yarns and textile fabrics. The three-year project with seven academic and industry partners is funded through the ERA-NET Scheme of the 7th EU Framework Programme.
- EUCODIS Bioscience introduces new panel of Peroxidases
- INVISTA and EUCODIS Bioscience collaborate on development of enzymes for production of industrial chemicals
- CTAT: Further proof-of-concept data presented at PEGS Boston 2014
- EUCODIS successfully manufactured ferritin at industrial pilot scale for BiAqua